Recipient and kidney graft outcomes of deceased donors with human immunodeficiency virus in the United States.
HIV
disease recurrence
glomerulonephritis
living related donor
long-term outcomes
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
17
05
2023
received:
11
11
2022
accepted:
16
06
2023
medline:
15
8
2023
pubmed:
11
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
The HIV Organ Policy Equity (HOPE) act afforded transplantation of organs from donors who have HIV. Herein we compared the long-term outcomes of recipients with HIV by donor HIV testing status. Using the Scientific Registry of Transplant Recipients, we identified all primary adult kidney transplant recipients who were HIV-positive between 1/1/16-12/31/21. Recipients were grouped into three cohorts according to the donor HIV status based on antibody (Ab) and nucleic acid testing (NAT): Donor Ab-/NAT- (n = 810), Donor Ab+ /NAT- (n = 98), and Donor Ab+/NAT+ (n = 90). We compared recipient and death-censored graft survival (DCGS) by donor HIV testing status using Kaplan-Meier curves and Cox proportional hazards regression, censored at 3 years posttransplant. Secondary outcomes were delayed graft function (DGF) and the following 1-year outcomes: acute rejection, re-hospitalization, and serum creatinine. In Kaplan-Meier analyses, patient survival and DCGS were similar by donor HIV status (log rank p = .667; log rank p = .388). DGF occurred more frequently in donors with HIV Ab-/NAT- testing compared with Ab+/NAT- or Ab+/NAT+ testing (38.0% vs. 28.6% vs. 26.7%, p = .028). Average dialysis time before transplant was twice as long for recipients who received organs from donors with Ab-/NAT- testing (p < .001). Acute rejection, re-hospitalization and serum creatinine at 12 months did not differ between the groups. Patient and allograft survival for recipients living with HIV remains comparable irrespective of donor HIV testing status. Utilizing kidneys from deceased donors with HIV Ab+/NAT- or Ab+/NAT+ testing shortens dialysis time prior to transplant.
Sections du résumé
BACKGROUND
BACKGROUND
The HIV Organ Policy Equity (HOPE) act afforded transplantation of organs from donors who have HIV. Herein we compared the long-term outcomes of recipients with HIV by donor HIV testing status.
METHODS
METHODS
Using the Scientific Registry of Transplant Recipients, we identified all primary adult kidney transplant recipients who were HIV-positive between 1/1/16-12/31/21. Recipients were grouped into three cohorts according to the donor HIV status based on antibody (Ab) and nucleic acid testing (NAT): Donor Ab-/NAT- (n = 810), Donor Ab+ /NAT- (n = 98), and Donor Ab+/NAT+ (n = 90). We compared recipient and death-censored graft survival (DCGS) by donor HIV testing status using Kaplan-Meier curves and Cox proportional hazards regression, censored at 3 years posttransplant. Secondary outcomes were delayed graft function (DGF) and the following 1-year outcomes: acute rejection, re-hospitalization, and serum creatinine.
RESULTS
RESULTS
In Kaplan-Meier analyses, patient survival and DCGS were similar by donor HIV status (log rank p = .667; log rank p = .388). DGF occurred more frequently in donors with HIV Ab-/NAT- testing compared with Ab+/NAT- or Ab+/NAT+ testing (38.0% vs. 28.6% vs. 26.7%, p = .028). Average dialysis time before transplant was twice as long for recipients who received organs from donors with Ab-/NAT- testing (p < .001). Acute rejection, re-hospitalization and serum creatinine at 12 months did not differ between the groups.
CONCLUSIONS
CONCLUSIONS
Patient and allograft survival for recipients living with HIV remains comparable irrespective of donor HIV testing status. Utilizing kidneys from deceased donors with HIV Ab+/NAT- or Ab+/NAT+ testing shortens dialysis time prior to transplant.
Substances chimiques
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14093Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med. 2010;362(24):2336-2337.
Boyarsky BJ, Hall EC, Singer AL, Montgomery RA, Gebo KA, Segev DL. Estimating the potential pool of HIV-infected deceased organ donors in the United States. Am J Transplant. 2011;11(6):1209-1217.
Durand CM, Halpern SE, Bowring MG, et al. Organs from deceased donors with false-positive HIV screening tests: An unexpected benefit of the HOPE act. Am J Transplant. 2018;18(10):2579-2586.
Durand CM, Werbel W, Doby B, et al. Clarifying the HOPE Act landscape: The challenge of donors with false-positive HIV results. Am J Transplant. 2020;20(2):617-619.
Wilk AR, Hunter RA, McBride MA, Klassen DK. National landscape of HIV+ to HIV+ kidney and liver transplantation in the United States. Am J Transplant. 2019;19(9):2594-2605.
Locke JE, Mehta S, Sawinski D, et al. Access to kidney transplantation among HIV-infected waitlist candidates. Clin J Am Soc Nephrol. 2017;12(3):467-475.
Durand CM, Florman S, Motter JD, et al. HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV. Am J Transplant. 2022;22(3):853-864.
Durand CM, Zhang W, Brown DM, et al. A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action. Am J Transplant. 2021;21(5):1754-1764.
Cohen JB, Locke JE, Shelton B, et al. Disparity in access to kidney allograft offers among transplant candidates with human immunodeficiency virus. Clin Transplant. 2019;33(2):e13466.
Muller E, Barday Z. HIV-positive kidney donor selection for HIV-positive transplant recipients. J Am Soc Nephrol. 2018;29(4):1090-1095.
Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation-results at 3 to 5 years. N Engl J Med. 2015;372(7):613-620.
Selhorst P, Combrinck CE, Manning K, et al. Longer-term outcomes of HIV-positive-to-HIV-positive renal transplantation. N Engl J Med. 2019;381(14):1387-1389.
Irish WD, Ilsley JN, Schnitzler MA, Feng S, Brennan DC. A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation. Am J Transplant. 2010;10(10):2279-2286.
Locke JE, Mehta S, Reed RD, et al. A National Study of Outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol. 2015;26(9):2222-2229.
Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004-2014.
Locke JE, James NT, Mannon RB, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation. 2014;97(4):446-450.
Stock PG. Strengths and weaknesses of using SRTR data to shape the management of the HIV-infected kidney transplant recipient. Am J Transplant. 2017;17(12):3001-3002.
Sawinski D, Shelton BA, Mehta S, et al. Impact of protease inhibitor-based anti-retroviral therapy on outcomes for HIV+ kidney transplant recipients. Am J Transplant. 2017;17(12):3114-3122.
Petersen J, Monteiro M, Dalal S, Jhala D. Reducing false-positive results with fourth-generation HIV testing at a Veterans Affairs Medical Center. Fed Pract. 2021;38(5):232-237.
Laboratories CfDCaPaAoPH. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. 2014. In:2014.
Gill MJ, Rachlis A, Anand C. Five cases of erroneously diagnosed HIV infection. Can Med Assoc J. 1991;145(12):1593-1595.
Wood RW, Dunphy C, Okita K, Swenson P. Two “HIV-infected” persons not really infected. Arch Inter Med. 2003;163(15):1857-1859.
Esteva MH, Blasini AM, Ogly D, Rodriguez MA. False positive results for antibody to HIV in two men with systemic lupus erythematosus. Annal Rheum Dis. 1992;51(9):1071-1073.
Shida S, Takahashi N, Fujishima N, et al. False-positive human immunodeficiency virus antibody test and autoimmune hemolytic anemia in a patient with angioimmunoblastic T-cell lymphoma. Intern Med. 2011;50(20):2383-2387.